• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一名具有广泛中和活性的HIV-1 B'亚型感染血浆供体中的病毒进化与中和敏感性

Virus Evolution and Neutralization Sensitivity in an HIV-1 Subtype B' Infected Plasma Donor with Broadly Neutralizing Activity.

作者信息

Hu Yuanyuan, Zou Sen, Wang Zheng, Liu Ying, Ren Li, Hao Yanling, Sun Shasha, Hu Xintao, Ruan Yuhua, Ma Liying, Shao Yiming, Hong Kunxue

机构信息

State Key Laboratory of Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.

出版信息

Vaccines (Basel). 2021 Mar 25;9(4):311. doi: 10.3390/vaccines9040311.

DOI:10.3390/vaccines9040311
PMID:33805985
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8064334/
Abstract

We sought to analyze the evolutionary characteristics and neutralization sensitivity of viruses in a human immunodeficiency virus type 1 (HIV-1) subtype B' infected plasma donor with broadly neutralizing activity, which may provide information for new broadly neutralizing antibodies (bNAbs) isolation and immunogen design. A total of 83 full-length envelope genes were obtained by single-genome amplification (SGA) from the patient's plasma at three consecutive time points (2005, 2006, and 2008) spanning four years. In addition, 28 Env-pseudotyped viruses were constructed and their neutralization sensitivity to autologous plasma and several representative bNAbs were measured. Phylogenetic analysis showed that these env sequences formed two evolutionary clusters (Cluster I and II). Cluster I viruses vanished in 2006 and then appeared as recombinants two years later. In Cluster II viruses, the V1 length and N-glycosylation sites increased over the four years of the study period. Most viruses were sensitive to concurrent and subsequent autologous plasma, and to bNAbs, including 10E8, PGT121, VRC01, and 12A21, but all viruses were resistant to PGT135. Overall, 90% of Cluster I viruses were resistant to 2G12, while 94% of Cluster II viruses were sensitive to 2G12. We confirmed that HIV-1 continued to evolve even in the presence of bNAbs, and two virus clusters in this donor adopted different escape mechanisms under the same humoral immune pressure.

摘要

我们试图分析一名具有广泛中和活性的人类免疫缺陷病毒1型(HIV-1)B'亚型感染血浆供体中病毒的进化特征和中和敏感性,这可能为新型广泛中和抗体(bNAbs)的分离和免疫原设计提供信息。通过单基因组扩增(SGA),在跨越四年的三个连续时间点(2005年、2006年和2008年)从患者血浆中总共获得了83个全长包膜基因。此外,构建了28种Env假型病毒,并测量了它们对自体血浆和几种代表性bNAbs的中和敏感性。系统发育分析表明,这些env序列形成了两个进化簇(簇I和簇II)。簇I病毒在2006年消失,两年后作为重组体出现。在簇II病毒中,在研究的四年期间,V1长度和N-糖基化位点增加。大多数病毒对同时期和后续的自体血浆以及bNAbs敏感,包括10E8、PGT121、VRC01和12A21,但所有病毒对PGT135耐药。总体而言,90%的簇I病毒对2G12耐药,而94%的簇II病毒对2G12敏感。我们证实,即使在存在bNAbs的情况下,HIV-1仍在继续进化,并且该供体中的两个病毒簇在相同的体液免疫压力下采用了不同的逃逸机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/946a/8064334/d6c541a6af6e/vaccines-09-00311-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/946a/8064334/ba0916a05a8c/vaccines-09-00311-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/946a/8064334/b626fcc0b32b/vaccines-09-00311-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/946a/8064334/439e26f78be9/vaccines-09-00311-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/946a/8064334/d6c541a6af6e/vaccines-09-00311-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/946a/8064334/ba0916a05a8c/vaccines-09-00311-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/946a/8064334/b626fcc0b32b/vaccines-09-00311-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/946a/8064334/439e26f78be9/vaccines-09-00311-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/946a/8064334/d6c541a6af6e/vaccines-09-00311-g004.jpg

相似文献

1
Virus Evolution and Neutralization Sensitivity in an HIV-1 Subtype B' Infected Plasma Donor with Broadly Neutralizing Activity.一名具有广泛中和活性的HIV-1 B'亚型感染血浆供体中的病毒进化与中和敏感性
Vaccines (Basel). 2021 Mar 25;9(4):311. doi: 10.3390/vaccines9040311.
2
Neutralization Sensitivity of HIV-1 CRF07_BC From an Untreated Patient With a Focus on Evolution Over Time.HIV-1 CRF07_BC 对未经治疗的患者的中和敏感性,重点关注随时间的演变。
Front Cell Infect Microbiol. 2022 Mar 17;12:862754. doi: 10.3389/fcimb.2022.862754. eCollection 2022.
3
Subtle Longitudinal Alterations in Env Sequence Potentiate Differences in Sensitivity to Broadly Neutralizing Antibodies following Acute HIV-1 Subtype C Infection.急性 HIV-1 型 C 亚型感染后,Env 序列的细微纵向改变增强了对广泛中和抗体敏感性的差异。
J Virol. 2022 Dec 21;96(24):e0127022. doi: 10.1128/jvi.01270-22. Epub 2022 Dec 1.
4
Sensitivity to Broadly Neutralizing Antibodies of Recently Transmitted HIV-1 Clade CRF02_AG Viruses with a Focus on Evolution over Time.对具有时间进化特征的近期传播的 HIV-1 流行重组型 CRF02_AG 病毒的广泛中和抗体的敏感性。
J Virol. 2019 Jan 4;93(2). doi: 10.1128/JVI.01492-18. Print 2019 Jan 15.
5
Characteristics of Envelope Genes in a Chinese Chronically HIV-1 Infected Patient With Broadly Neutralizing Activity.一名具有广泛中和活性的中国慢性HIV-1感染患者包膜基因的特征
Front Microbiol. 2019 May 24;10:1096. doi: 10.3389/fmicb.2019.01096. eCollection 2019.
6
Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.广泛中和性抗HIV-1抗体对在外周血单核细胞中产生的B亚型临床分离株的中和活性
J Virol. 2018 Feb 12;92(5). doi: 10.1128/JVI.01883-17. Print 2018 Mar 1.
7
Evaluation of susceptibility of HIV-1 CRF01_AE variants to neutralization by a panel of broadly neutralizing antibodies.评估HIV-1 CRF01_AE变异体对一组广泛中和抗体中和作用的敏感性。
Arch Virol. 2018 Dec;163(12):3303-3315. doi: 10.1007/s00705-018-4011-7. Epub 2018 Sep 8.
8
A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex.婴儿来源的 HIV-1 包膜糖蛋白中的一个罕见突变改变了二聚体间的稳定性,并影响了针对三聚体顶部的广谱中和抗体的敏感性。
J Virol. 2020 Sep 15;94(19). doi: 10.1128/JVI.00814-20.
9
Viral Characteristics Associated with Maintenance of Elite Neutralizing Activity in Chronically HIV-1 Clade C-Infected Monozygotic Pediatric Twins.与慢性 HIV-1 型 C 群感染者同卵双胞胎中保持精英中和活性相关的病毒特征。
J Virol. 2019 Aug 13;93(17). doi: 10.1128/JVI.00654-19. Print 2019 Sep 1.
10
An HIV-1 Broadly Neutralizing Antibody from a Clade C-Infected Pediatric Elite Neutralizer Potently Neutralizes the Contemporaneous and Autologous Evolving Viruses.来自 C 型 HIV-1 感染者的广谱中和抗体能有效中和同时代和同源进化的病毒。
J Virol. 2019 Feb 5;93(4). doi: 10.1128/JVI.01495-18. Print 2019 Feb 15.

引用本文的文献

1
Identification of an IGHV3-53-Encoded RBD-Targeting Cross-Neutralizing Antibody from an Early COVID-19 Convalescent.从早期新冠康复者中鉴定出一种IGHV3-53编码的靶向RBD的交叉中和抗体。
Pathogens. 2024 Mar 23;13(4):272. doi: 10.3390/pathogens13040272.
2
Neutralization Sensitivity and Evolution of Virus in a Chronic HIV-1 Clade B Infected Patient with Neutralizing Activity against Membrane-Proximal External Region.一名慢性HIV-1 B亚型感染患者中对膜近端外部区域具有中和活性的病毒的中和敏感性及进化
Pathogens. 2023 Mar 22;12(3):497. doi: 10.3390/pathogens12030497.
3
Replication in the presence of dengue convalescent serum impacts Zika virus neutralization sensitivity and fitness.

本文引用的文献

1
Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention.用于 HIV-1 预防的疫苗和广泛中和抗体。
Annu Rev Immunol. 2020 Apr 26;38:673-703. doi: 10.1146/annurev-immunol-080219-023629.
2
A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses.一种用于诱导广泛中和抗体反应的通用 HIV 疫苗设计策略。
Science. 2019 Dec 6;366(6470). doi: 10.1126/science.aax4380. Epub 2019 Oct 31.
3
Characteristics of Envelope Genes in a Chinese Chronically HIV-1 Infected Patient With Broadly Neutralizing Activity.
在登革热恢复期血清存在的情况下进行复制会影响寨卡病毒的中和敏感性和适应性。
Front Cell Infect Microbiol. 2023 Mar 9;13:1130749. doi: 10.3389/fcimb.2023.1130749. eCollection 2023.
4
Subtle Longitudinal Alterations in Env Sequence Potentiate Differences in Sensitivity to Broadly Neutralizing Antibodies following Acute HIV-1 Subtype C Infection.急性 HIV-1 型 C 亚型感染后,Env 序列的细微纵向改变增强了对广泛中和抗体敏感性的差异。
J Virol. 2022 Dec 21;96(24):e0127022. doi: 10.1128/jvi.01270-22. Epub 2022 Dec 1.
5
Unique profile of predominant CCR5-tropic in CRF07_BC HIV-1 infections and discovery of an unusual CXCR4-tropic strain.主要为 CCR5 嗜性的 CRF07_BC HIV-1 感染的独特特征及一种不寻常的 CXCR4 嗜性株的发现。
Front Immunol. 2022 Sep 23;13:911806. doi: 10.3389/fimmu.2022.911806. eCollection 2022.
6
Neutralization Sensitivity of HIV-1 CRF07_BC From an Untreated Patient With a Focus on Evolution Over Time.HIV-1 CRF07_BC 对未经治疗的患者的中和敏感性,重点关注随时间的演变。
Front Cell Infect Microbiol. 2022 Mar 17;12:862754. doi: 10.3389/fcimb.2022.862754. eCollection 2022.
一名具有广泛中和活性的中国慢性HIV-1感染患者包膜基因的特征
Front Microbiol. 2019 May 24;10:1096. doi: 10.3389/fmicb.2019.01096. eCollection 2019.
4
Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic.临床应用中的广谱中和抗 HIV-1 单克隆抗体。
Nat Med. 2019 Apr;25(4):547-553. doi: 10.1038/s41591-019-0412-8. Epub 2019 Apr 1.
5
An HIV-1 Broadly Neutralizing Antibody from a Clade C-Infected Pediatric Elite Neutralizer Potently Neutralizes the Contemporaneous and Autologous Evolving Viruses.来自 C 型 HIV-1 感染者的广谱中和抗体能有效中和同时代和同源进化的病毒。
J Virol. 2019 Feb 5;93(4). doi: 10.1128/JVI.01495-18. Print 2019 Feb 15.
6
HIV Broadly Neutralizing Antibodies: VRC01 and Beyond.HIV 广谱中和抗体:VRC01 及其他。
Adv Exp Med Biol. 2018;1075:53-72. doi: 10.1007/978-981-13-0484-2_3.
7
Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail.广谱中和抗体鸡尾酒可预防混合 SHIV 挑战
Sci Transl Med. 2017 Sep 20;9(408). doi: 10.1126/scitranslmed.aao4235.
8
Serum glycan-binding IgG antibodies in HIV-1 infection and during the development of broadly neutralizing responses.HIV-1 感染和广谱中和反应发展过程中血清糖基结合 IgG 抗体。
AIDS. 2017 Oct 23;31(16):2199-2209. doi: 10.1097/QAD.0000000000001643.
9
Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller.一名病毒血症控制者体内强效HIV-1广谱中和抗体与抗体敏感病毒的共存情况。
Sci Transl Med. 2017 Jan 18;9(373). doi: 10.1126/scitranslmed.aal2144.
10
Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth.鉴定一种对HIV具有近泛中和广度的CD4结合位点抗体。
Immunity. 2016 Nov 15;45(5):1108-1121. doi: 10.1016/j.immuni.2016.10.027.